A neurologist just published a video explaining exactly what NIH walked away
from and what it means for the 7.4 million Americans currently living with
Alzheimer's. Watch before it's pulled.



<[link removed]>

August 20


 



RFK Jr. reveals how to reverse memory loss

See Here →
<[link removed]>

 






RFK Jr. told the Senate budget hearing something most people ignored.

"NIH went off the rails on Alzheimer's research 20 years ago."

He said they locked onto one theory. Refused to fund anything else. Buried
every alternative.

The mainstream called him a conspiracy theorist.

But here's the thing...

A natural compound that triggers a 1,452% surge in the brain's primary repair
protein has been sitting in published research since 1996.

Pfizer's own lab found it.

Your doctor has never mentioned it.

Maybe RFK has a point.

<[link removed]>
See the suppressed research RFK says your doctor doesn't know about
<[link removed]>

Stay safe,

P.S. A neurologist just published a video explaining exactly what NIH walked
away from and what it means for the 7.4 million Americans currently living with
Alzheimer's. Watch before it's pulled.


If you'd rather not receive these emails, you can unsubscribe here
<[link removed]>
.
 








CONNOR'S HEALTH NOTES

Improvement Has to Be Measured Against Something

Connor Hill · InsightfulWord · August 19, 2026

A cognitive test score that goes up is one of the most persuasive things a
person can be shown, and one of the least conclusive. The reason is not that
the score is wrong. It is that a score measured twice, in the same person,
moves for at least four reasons that have nothing to do with whether anything
was treated.

The first is practice. Cognitive instruments — the Mini-Mental State
Examination, the Montreal Cognitive Assessment, the pencil-and-paper batteries
used in research — are tests, and people get better at tests by taking them.
The effect has been documented directly in patients with diagnosed Alzheimer's
disease, who improved on repeated administration of the same instrument over
short intervals despite an underlying condition that does not improve. In
healthy older adults the practice effect is larger still, large enough that
trial designers now build in a preliminary assessment specifically to burn it
off before the real baseline is recorded.

The second is measurement error. Every one of these instruments has a
documented range within which a change is indistinguishable from noise. For the
common screening tools, published estimates of the minimum detectable change in
older community-dwelling adults run to several points — which is to say a
person can score four points higher on a second sitting for no reason at all.

The third is regression to the mean. People are enrolled in studies, or seek
help, when they are doing badly. A person assessed on an unusually poor day
will, on average, do better the next time regardless of what happens in
between. This is not a psychological claim. It is a statistical property of any
repeated measurement with a random component, and it operates most strongly on
exactly the people most likely to be recruited.

The fourth is expectation. Participants who know they are receiving an
intervention, and examiners who know which participants those are, both shift
results in the expected direction. This is the reason blinding exists, and it
is the first thing to disappear when a study is conducted as an open protocol.

None of these four mechanisms requires anyone to be dishonest. They operate on
careful, well-intentioned investigators reporting exactly what they observed.
What removes them is not sincerity. It is a comparison group that experiences
all four and does not receive the intervention.

What follows is what a series of individual cases can and cannot establish,
what the controlled evidence on multidomain lifestyle intervention actually
shows, how the licensed drug effects compare against the threshold clinicians
consider meaningful, and the questions worth putting to a specialist.

What a Case Series Can Establish

A case series is a record of what happened to a group of patients who received
something. It is a legitimate and useful form of medical evidence, and it sits
near the bottom of the hierarchy for a specific reason rather than a snobbish
one.

Its strengths are real. A case series can establish that an outcome is
possible, can generate a hypothesis worth testing, and can surface a safety
signal quickly. Several major therapeutic advances began as somebody noticing
an unexpected recovery and writing it down.

Its limitation is singular and fatal to causal claims. Because everyone in the
series received the intervention, there is no observation of what would have
happened otherwise. Every one of the four mechanisms above remains fully in
play, and no amount of detail in the write-up removes them. Publication and
peer review do not remove them either; peer review checks whether a study is
reported adequately and whether its conclusions follow from its design. A
well-reported case series that concludes causation has been reviewed and is
still a case series.

Two further features deserve attention when reading one. Patients who improve
are more likely to return for follow-up assessment than patients who
deteriorate, which biases the reported sample upward. And a protocol combining
many simultaneous changes — diet, sleep, exercise, supplements, treatment of
other conditions — cannot attribute any result to any component, even if the
result is real.

There is also a selection effect at the point of writing. A clinician with a
hundred patients who publishes an account of the ones who improved has produced
a truthful document about a non-random subset. The reader has no way to
establish the denominator, and the denominator is the whole question. This is
not a hypothetical failure mode; it is the ordinary way case series come to
exist, because nobody writes up the patients in whom nothing happened.


The Score Moves Even When Nothing Does

The practical size of these effects is worth stating in numbers, because the
abstract version is easy to nod at and hard to apply.

Studies of test-retest performance on standard cognitive screening instruments
have repeatedly found improvement on second administration in populations with
established cognitive impairment. Work on serial assessment in preclinical
Alzheimer's research has shown practice effects persisting across annual
testing intervals, not merely across weeks, which is long enough to cover the
entire follow-up period of many small studies.


🩹 Health Stat of the Day

0.45 points

The difference in 18-month change on the Clinical Dementia Rating Sum of Boxes
between lecanemab and placebo in the CLARITY-AD trial — a 27 percent slowing of
decline. Published estimates of the minimal clinically important difference on
that scale in mild cognitive impairment are around one point. Sources:New
England Journal of Medicine, CLARITY-AD; eNeuro, contextual analysis of
anti-amyloid antibody trial results.


Support or oppose: should uncontrolled studies be allowed to use the word
"reversal"?

Supporters of restraint argue that the word describes a causal claim no
single-arm study can support, that it travels far beyond the paper into
marketing, and that families make decisions on it. Opponents answer that
describing what was observed is not the same as claiming why, that journals
should not police vocabulary, and that a rule against plain description would
slow legitimate hypothesis generation. Where would you draw the line?Hit reply
— one line is enough.

The consequence for reading a study is straightforward. A reported improvement
smaller than the instrument's minimum detectable change carries no information
about the individual. An improvement in an uncontrolled group carries no
information about the intervention. Both statements can be true of a study that
is honestly conducted and correctly reported.


What the Controlled Evidence on Lifestyle Actually Found

The comparison worth making is not between a case series and nothing. It is
between a case series and a randomized trial testing a similar idea, because
one exists and its results are more interesting than either camp usually admits.

The U.S. POINTER trial randomized 2,111 older adults at elevated risk of
cognitive decline to either a structured multidomain program — supervised
exercise, a specified dietary pattern, cognitive challenge, social engagement,
and monitoring of cardiovascular risk factors — or a self-guided version of the
same advice. Both arms were active. Neither was a placebo.

Over two years, the structured arm improved on global cognition by 0.029
standard deviations per year more than the self-guided arm, a difference that
was statistically significant. Executive function moved similarly. Processing
speed trended in the same direction without reaching significance, and memory
showed no group difference.


Context — what this is not a reason to change

Nothing here is a reason to stop or alter a prescribed medication, and
stopping treatment for blood pressure, diabetes or cholesterol on the strength
of a lifestyle finding would remove protection whose benefit is far better
established than any cognitive effect. New memory difficulty also warrants
assessment rather than self-management: sudden confusion, difficulty finding
words that appears abruptly, personality change, or memory loss accompanied by
weakness, gait change or headache are reasons to seek medical evaluation
promptly, because a proportion of cognitive presentations have causes that are
treatable when identified — thyroid disease, vitamin B12 deficiency, medication
interactions, depression, sleep apnoea and normal pressure hydrocephalus among
them.

That result deserves to be read in both directions. It is genuine, controlled
evidence that a structured program of ordinary behaviors produced a measurable
cognitive benefit in two years. It is also a small effect, in a comparison
against people who were given the same advice without supervision, in a
population without dementia. It is not a reversal of anything, and the
investigators did not describe it as one.

The honest summary is that the direction of effect for multidomain lifestyle
intervention is now supported by randomized evidence, and the magnitude is
modest. That is a more useful sentence than either the dismissal or the
enthusiasm.


Where the Licensed Drug Data Sits

The anti-amyloid antibodies provide the other calibration point, and the
numbers are instructive precisely because they come from large, blinded,
placebo-controlled trials.

In CLARITY-AD, patients receiving lecanemab declined by 1.21 points on the
Clinical Dementia Rating Sum of Boxes over eighteen months against 1.66 in the
placebo group — a difference of 0.45 points, characterized as a 27 percent
slowing and equivalent to roughly a six-month delay. The donanemab trial
reported a similar structure of result on a different scale, with a delay
estimated at about four and a half months.

Set against a minimal clinically important difference on that scale estimated
at around one point, the effects are real, statistically robust, and smaller
than the threshold at which a clinician would expect a family to notice the
difference. They also carry a documented risk of amyloid-related imaging
abnormalities requiring monitored infusion and repeat scanning.

The relevant point is not that these drugs are disappointing, though many
clinicians consider them so. It is that this is what a well-powered,
placebo-controlled effect on Alzheimer's progression looks like when it is
measured properly: a fraction of a point, detectable only in aggregate. Any
claim of a larger effect from a smaller and less controlled study is a claim
that something extraordinary happened, and extraordinary results are exactly
the ones most often produced by the four mechanisms described at the start.


Four Questions Before Acting on a Study

For a person with a memory concern, or watching one develop in a spouse, a
short list of questions does more work than any single study.

Ask what the diagnosis is based on. Cognitive complaints are not a diagnosis,
and the evaluation that distinguishes Alzheimer's disease from the treatable
causes listed above involves history, examination, blood work and usually
imaging. Blood-based biomarker tests measuring phosphorylated tau have become
available and cleared for clinical use, and they change the diagnostic pathway
substantially — but a positive biomarker in a person without symptoms is not a
diagnosis either.

Ask what the comparison group was, of any study cited. If the answer is that
there was not one, the study describes what happened and not why.

Ask which single change is being proposed and what would count as it not
working. A protocol with fifteen components and no stopping rule can absorb any
outcome.

Ask about the modifiable risk factors with the strongest evidence behind them,
which are unglamorous and well documented: blood pressure control in midlife,
hearing correction, physical activity, treatment of sleep disorders, smoking
cessation, and management of diabetes. The effect sizes are individually modest
and the evidence base behind them is far larger than that behind anything sold
as a discovery.


The bill, not the debate

The strongest controlled effect on Alzheimer's progression anyone has yet
produced is under half a point on an eighteen-point scale, and it required a
trial of well over a thousand patients to detect. That is the calibration
against which every other claim should be read. If a study is presented to you
as a breakthrough, is the first question you ask what the people who did not
receive it experienced?Connor Hill reads every reply.


Sources checked: Baker et al. — Structured vs Self-Guided Multidomain
Lifestyle Interventions for Global Cognitive Function: The US POINTER
Randomized Clinical Trial, JAMA
<[link removed]> · van Dyck et al. —
Lecanemab in Early Alzheimer's Disease, New England Journal of Medicine
<[link removed]> · eNeuro — contextual
analysis of lecanemab, donanemab and anti-amyloid antibody effect sizes
<[link removed]> · Neurology —
repeated exposure to the Mini-Mental State Examination produces a practice
effect in Alzheimer's disease
<[link removed]> · Alzheimer's & Dementia:
Translational Research — practice effects due to serial cognitive assessment in
preclinical Alzheimer's trials
<[link removed]> ·
National Institute on Aging — assessing memory problems and causes of cognitive
change <[link removed]>


Connor Hill · InsightfulWord





You’re receiving this email from Insightful Word (IW), a brand of TerraTrance
Technologies, LLC.

Our mailing address: 200 Broadway Blvd NEAlbuquerque, NM 87102



Have a question or need assistance? Reply directly to this email or contact us
[email protected] <mailto:[email protected]>



The content of this email may not be copied, reproduced, forwarded, shared, or
distributed without the prior written consent of TerraTrance Technologies, LLC.

Privacy Policy <[link removed]>
Terms & Conditions <[link removed]>
Unsubscribe
<[link removed]>



© 2026 Insightful Word (IW). All Rights Reserved.